Pharma News in Global Health and Sustainability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma News in Global Health and Sustainability
A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 9, Issue 8

GlaxoSmithKline (GSK) and Save the Children have launched a $1- million Healthcare Innovation Award to identify and reward innovations in healthcare which have proven successful in reducing child deaths in developing countries. From June 27 to August 26, 2013, organizations from across the developing world can nominate examples of innovative healthcare approaches they have discovered or implemented. These approaches must have resulted in tangible improvements to under-age-five child survival rates, be sustainable, and have the potential to be scaled-up and replicated. Co-chaired by Sir Andrew Witty, CEO of GSK, and Justin Forsyth, CEO of Save the Children, the judging anel, made up of experts from the fields of public health, science and academia, will award $250,000 to the best healthcare innovation to further progress their work. An additional $750,000 is available for runners-up awards. The award will also provide a platform for winning organizations to showcase their innovations and share information to enable others with an interest in improving healthcare to adapt and replicate successful interventions and create more positive change for children in their own country and beyond.

Sanofi and GDF SUEZ, an energy firm, have signed an agreement to strengthen their collaboration for implementing projects in the field of energy at Sanofi industrial sites. The five-year contract includes mainly renewable energy production and distribution systems. Building on an initial agreement signed in March 2012 for Europe and Turkey, the two groups have expanded their collaboration to include sites in the United States, Canada, Mexico, Brazil, China, and Singapore. All Sanofi’s production lines will be included: chemicals, pharmaceuticals, vaccines, biotechnology, and animal health. The initial three-year term contract is extended to five years.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here